![]() | |
| Clinical data | |
|---|---|
| Other names | 1-Butyryl-LSD; X-LSD |
| Routes of administration | Oral |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C24H31N3O2 |
| Molar mass | 393.531 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
1B-LSD, also known as 1-butyryl-LSD, is a psychedelic drug of the lysergamide family and an acylated derivative of lysergic acid diethylamide (LSD) which has been sold as a designer drug.1
Use and effects
Interactions
Pharmacology
Pharmacodynamics
1B-LSD has been found to produce psychedelic-like effects in rodents similarly to LSD, though with only around 1/7 the potency of LSD itself.234
Chemistry
Analogues
Related compounds include 1cP-LSD, 1P-LSD, 1V-LSD, ALD-52 (1A-LSD), 1cP-AL-LAD, AL-LAD, ETH-LAD, 1P-ETH-LAD, PRO-LAD, LSM-775, and LSZ, among others.
Society and culture
Legal status
Canada
1B-LSD is not a controlled substance in Canada as of 2025.5
Singapore
1B-LSD is illegal in Singapore.6 Sweden's public health agency suggested classifying 1B-LSD as a hazardous substance, on June 24, 2019.7
United States
1B-LSD is not an explicitly controlled substance in the United States.8 However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
References
References
- Tsochatzis E, Lopes JA, Reniero F, Holland M, Åberg J, Guillou C (February 2020). "Identification of 1-Butyl-Lysergic Acid Diethylamide (1B-LSD) in Seized Blotter Paper Using an Integrated Workflow of Analytical Techniques and Chemo-Informatics". Molecules. 25 (3): 712. doi:10.3390/molecules25030712. PMC 7037844. PMID 32045999.
- Wagmann L, Richter LH, Kehl T, Wack F, Bergstrand MP, Brandt SD, et al. (July 2019). "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures" (PDF). Analytical and Bioanalytical Chemistry. 411 (19): 4751–4763. doi:10.1007/s00216-018-1558-9. PMID 30617391. S2CID 58615418.
- Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Dowling G, et al. (August 2019). "Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)". Drug Testing and Analysis. 11 (8): 1122–1133. doi:10.1002/dta.2613. PMC 6899222. PMID 31083768.
- Halberstadt AL, Chatha M, Klein AK, McCorvy JD, Meyer MR, Wagmann L, et al. (August 2020). "Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)" (PDF). Neuropharmacology. 172 107856. doi:10.1016/j.neuropharm.2019.107856. PMC 9191647. PMID 31756337. S2CID 208155327.
- "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
- "Misuse of Drugs Act - Singapore Statutes Online". sso.agc.gov.sg.
- "Åtta ämnen föreslås klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. 24 June 2019.
- Orange Book: List of Controlled Substances and Regulated Chemicals (January 2026) (PDF), United States: U.S. Department of Justice: Drug Enforcement Administration (DEA): Diversion Control Division, January 2026
